Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Other Operating Expenses (2024 - 2025)

Intellia Therapeutics (NTLA) has disclosed Other Operating Expenses for 2 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 102.83% to $1.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$899000.0, a 97.24% increase, with the full-year FY2025 number at -$899000.0, up 97.24% from a year prior.
  • Other Operating Expenses was $1.8 million for Q4 2025 at Intellia Therapeutics, up from -$3.4 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $20.4 million in Q2 2024 to a low of -$62.0 million in Q4 2024.